Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

PCSK9 inhibitor reduces LDL-c in patients with HoFH

News - Apr. 1, 2020

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD
At the end of the FOURIER trial studying evolocumab, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Sustained efficacy and safety of PCSK9 antibody in HoFH and severe HeFH

Literature - Feb. 12, 2020 - Santos RD et al., - J Am Coll Cardiol. 2020

The open-label TAUSSIG study evaluated treatment with evolocumab during a median follow-up of 4.1 years and found a similar safety profile and good LDL-c lowering in HoFH and HeFH patients

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD
A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD
Prof. Laufs points out the new emphasis in the ESC/EAS Dyslipidaemia Guidelines on high-risk patients, and shares evidence that forms the rationale for the treatment recommendations.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

PCSK9i, changing practice in cardiology: The emerging story

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This video series addresses the role of PCSK9 inhibiting approaches in treating hypercholesterolemia and in preventing CV events in patients at high and very high CV risk. Member registration (free) is needed to enroll in this course.

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia
The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

PCSK9